strict warning: Only variables should be passed by reference in /home/biocance/public_html/modules/book/book.module on line 559.

12. Bibliografia

12.         Bibliografia

1.
1.American Cancer Society.: Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society, 2004
2.
ACOG committee opinion. Routine cancer screening. Number 185, September 1997 (replaces no. 128, October 1993). Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 59 (2): 157-61, 1997
3.
Antunes CM, Stro ley PD, Rosenshein NB, et al.: Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 300 (1): 9-13, 1979.
4.
Ball HG, Blessing JA, Lentz SS, et al.: A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 62 (2): 278-81, 1996.
5.
Bergman L, Beelen ML, Gallee MP, et al.: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 356 (9233): 881-7, 2000
6.
Cáncer del endometrio (PDQ): Tratamiento. Instituto Nacional del Cáncer. Ultima revisión 2/junio/2003
7.
Creutzberg CL, van Putten WL, Koper PC, et al.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 (9213): 1404-11, 2000.
8.
DuBeshter B, Warshal DP, Angel C, et al.: Endometrial carcinoma: the relevance of cervical cytology. Obstet Gynecol 77 (3): 458-62, 1991.
9.
Endometrial cancer (PDQ): Screening. Instituto Nacional del Cáncer. Ultima revisión 19/junio/2003.
10.
Endometrial cancer (PDQ): Prevention. Instituto Nacional del Cáncer. Ultima revisión 19/junio/2003.
11.
Enriori CL, Reforzo-Membrives J: Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review. Gynecol Oncol 17 (1): 1-21, 1984..
12.
Fornander T, Rutqvist LE, Cedermark B, et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1 (8630): 117-20, 1989.
13.
Glassburn JR, Brady LW, Grigsby PW. Endometrium: Chapter 63,. En Principles and Practice of Radiation Oncology, Third Edition, edited by C.A Pérez y L.W. Brady. Lippincott-Raven Publisehrs, Philadelphia, 1997. pp 1835-1851
14.
Greven KM, Curran WJ Jr, Whittington R, et al.: Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys 17 (1): 35-9, 1989.
15.
Homesley HD, Zaino R: Endometrial cancer: prognostic factors. Semin Oncol 21 (1): 71-8, 1994.
16.
Jick H, Walker AM, Rothman KJ: The epidemic of endometrial cancer: a commentary. Am J Public Health 70 (3): 264-7, 1980.
17.
Koss LG, Schreiber K, Oberlander SG, et al.: Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 64 (1): 1-11, 1984.
18.
Lentz SS: Advanced and recurrent endometrial carcinoma: hormonal therapy. Semin Oncol 21 (1): 100-6, 1994.
19.
Morrow CP, Bundy BN, Kurman RJ, et al.: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40 (1): 55-65, 1991
20.
Omura GA, Blessing JA, Major F, et al.: A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 3 (9): 1240-5, 1985.
21.
Trichopoulou A, Lagiou P, Kuper H, et al.: Cancer and Mediterranean dietary traditions. Cancer Epidemiol Biomarkers Prev 9 (9): 869-73, 2000.
22.
Watson P, Vasen HF, Mecklin JP, et al.: The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96 (6): 516-20, 1994.